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Abstract
Background: The adverse effects of tobacco abuse on cardiovascular outcomes are well-known.
However, the impact of passive smoke exposure on angina status and therapeutic response is less
well-established. We examined the impact of second-hand smoke (SHS) exposure on symptomatic
improvement in patients with chronic ischemic coronary disease undergoing enhanced external
counterpulsation (EECP).
Methods: This observational study included 1,026 non-smokers (108 exposed and 918 not-
exposed to SHS) from the Second International EECP Patient Registry. We also assessed angina
response in 363 current smokers. Patient demographics, symptomatic improvement and quality of
life assessment were determined by self-report prior and after EECP treatment.
Results: Non-smoking SHS subjects had a lower prevalence of prior revascularization (85% vs
90%), and had an increased prevalence of stroke (13% vs 7%) and prior smoking (72% vs 61%; all p
< 0.05) compared to non-smokers without SHS exposure. Despite comparable degrees of
coronary disease, baseline angina class, medical regimens and side effects during EECP, fewer SHS
non-smokers completed a full 35-hour treatment course (77% vs 85%, p = 0.020) compared to
non-smokers without SHS. Compared to non-smokers without SHS, non-smoking SHS subjects
had less angina relief after EECP (angina class decreased ≥ 1 class: 68% vs 79%; p = 0.0082), both
higher than that achieved in current smokers (66%). By multivariable logistic regression, SHS
exposure was an independent predictor of failure to symptomatic improvement after EECP among
non-smokers (OR 1.81, 95% confidence intervals 1.16–2.83).
Conclusion: Non-smokers with SHS exposure had an attenuated improvement in anginal
symptoms compared to those without SHS following EECP.
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Epidemiological evidence has unequivocally confirmed
that active smoking is a risk factor for cardiovascular dis-
ease and the leading cause of preventable death [1,2]. The
impact of passive smoking on the cardiovascular system
was recognized nearly two decades ago, when evidence of
the harmful effects of second-hand smoke (SHS) began to
emerge [3,4]. In the past decade, clinical data from the
Atherosclerosis Risk in Communities (ARIC) studies dem-
onstrated that both active and passive smoking were asso-
ciated with accelerated atherosclerosis progression [5].
Steenland et al reported that the risk of death due to car-
diovascular disease (CVD) increases by 30% in non-
smokers who live together with smokers [6]. Another
study suggested that in the United States more than
50,000 deaths annually from ischemic heart disease are
associated with SHS [7]. Epidemiological data suggest a
non-linear dose-response relationship between the inten-
sity of exposure to SHS and the risk of ischemic heart dis-
ease [8,9]. The excess risk of developing CVD amounts to
80% in active smokers at the age of 65, but it may also be
as high as 30% in passive smokers [10]. Using measure-
ments of the serum concentration of cotinine, a biomar-
ker of smoke exposure, in a large prospective population
study, Whincup et al recently concluded that the risk of
coronary heart disease related to passive smoke exposure
has probably been underestimated in earlier reports and
might, in fact, be very close to the risk reported for active
smokers [11].
Enhanced external counterpulsation (EECP) is a non-
invasive treatment for chronic, refractory angina that
involves the sequential inflation of three sets of lower-
extremity cuffs during diastole, leading to increased
venous return and cardiac output, systolic unloading, and
augmentation of the coronary artery perfusion pressure.
EECP has been shown to be effective in treating patients
with chronic ischemic coronary artery disease using vari-
ous measures, including improved functional class [12],
reduced anginal symptoms [13], improved quality-of-life
indices [14,15], improved stress cardionuclide perfusion
[16,17], increased exercise time [18,19], and increased
time to ST-segment depression [20]. Treatment with EECP
has also been demonstrated to increase nitric oxide levels
and decrease malondialdehyde, a marker of lipid peroxi-
dation, as well as to decrease endothelin-1 levels. Moreo-
ver, the benefit of EECP has been shown to be sustained
at 3- and 5-years after treatment by radionuclide stress
testing and quality-of-life measures [21,22].
There have been several emerging predictors of a lower
likehood of benefit from EECP treatment including the
presence of diabetes mellitus, prior surgical coronary
revascularization and heart failure [23]. Moreover, non-
smoking patients undergoing EECP treatment had clearly
improved symptom reduction compared to current smok-
ers [23]. We examined the impact of second-hand smoke
(SHS) exposure on angina status in patients with refrac-
tory angina undergoing EECP treatment.
Methods
The study group consisted of 1,026 non-smoking and 363
current smoking patients treated with EECP for refractory
angina enrolled in the Second International EECP Patient
Registry (IEPR-II). All patients signed informed written
consent prior to entry into the Registry, and the Registry
was approved by each center's institutional review board.
The primary analyses were performed comparing the non-
smokers without SHS exposure (n = 918) and non-smok-
ers with SHS exposure (n = 108). The IEPR-II enrolled
consecutive patients treated with EECP for chronic angina
in 73 US centers between 2002 and 2004. Briefly, the
IEPR-II collected patient demographics, medical history,
and coronary artery disease status before and after initia-
tion of EECP therapy. Data were collected prospectively
on anginal status according to the Canadian Cardiovascu-
lar Society Classification (CCSC), anti-anginal medication
use, quality of life and adverse clinical events. The present
analysis includes patients who were enrolled from sites
reporting ≥ 85% clinical follow-up. Since the IEPR aimed
to collect data on as broad a range of patients as possible,
the criteria for entry were only that the patient gave
informed consent and had at least one hour of EECP treat-
ment for chronic angina. The patients were interviewed by
telephone 6 months after the last EECP treatment session,
and yearly thereafter in order to record anginal status,
quality of life, and adverse cardiac events [24]. Non-smok-
ing is defined as no current tobacco smoking, by self-
report. SHS exposure was defined as any exposure to a
smoker living in the subject's household.
Statistical analysis
Data are presented as percentages for categorical variables
or as mean values and standard deviations for continuous
variables. Percentages and means are for patients with that
data item recorded. Data were missing for fewer than 3%
of each variable collected. Comparison of continuous var-
iables between groups was analyzed by Wilcoxon rank
tests and for categorical variables by chi-square, Fisher's
exact test or Mantel-Henzel tests, as appropriate. Multivar-
iable logistic regression analysis was used to determine
independent predictors of failure to achieve reduction in
angina. All baseline variables associated with the outcome
with a p-value of < 0.2 were entered into the preliminary
model. A backward selection procedure was used to deter-
mine independent, statistically significant predictors.
Two-tailed p-values < 0.05 were defined as significant.Page 2 of 7
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Of the 1,026 non-smoking patients who underwent EECP
treatment for angina, 108 (10.5%) reported current SHS
exposure. Demographic and clinical characteristics, such
as the prevalence of hypertension, diabetes, prior myocar-
dial infarction, heart failure, and anginal class, were simi-
lar among the two groups of non-smokers (Table 1).
There was a slight trend toward more women in the SHS
group (47%) compared to the non-SHS non-smokers
(26%; p = 0.74). The SHS subjects had a lower mean age
(66 ± 13 vs 68 ± 11 years, p = 0.033), with a lower propor-
tion of patients older than 65 years old (53% vs 63%; p =
0.039). SHS subjects had a higher percentage of previous
smoking and prior stroke, but had less reported hyperlip-
idemia. There was no difference in baseline angina sever-
ity between those with and without SHS exposure (Table
2).
More patients without SHS exposure finished the recom-
mended course of at least 35 hours of treatment (85.4%
vs. 76.9%, p = 0.020). The rate of major adverse cardiovas-
cular events (myocardial infarction, coronary artery
bypass graft surgery [CABG], percutaneous coronary inter-
vention, death) during the course of EECP therapy was
5.6% for the SHS group, compared to 2.8% for the non-
SHS group (p = 0.12). However, there was a higher inci-
dence of unstable angina during EECP in the SHS group
(8.3%) compared to the non-SHS non-smoker group
(2.6%; p = 0.0014). Other adverse events occurring during
the EECP treatment period occurred at a similar rate
(Table 3).
After completion of EECP therapy, angina decreased by ≥
1 class in 68% of the SHS non-smoker group, compared
to 79% of the non-SHS non-smoker group (p = 0.0082)
both higher than the 66% angina reduction achieved by
the current smoking group (Figure 1). Eleven percent of
the SHS non-smoker group remained in class IV angina
after EECP, compared to only 5% in the non-SHS non-
smoker group (p = 0.014). Medical therapy, including
beta-blocker, calcium channel blocker, angiotension-con-
verting enzyme inhibitor, angiotensin receptor blocker,
antiplatelet, diuretic and hypolipidemic medications,
remained similar after EECP in both non-smoking groups.
A multivariable logistic regression model showed the only
independent significant predictors of failure to achieve
angina reduction were: SHS exposure (odds ratio 1.81,
95% confidence interval 1.16–2.83), age ≤ 55 years (odds
ratio 2.10, 95% CI 1.41–3.13), and mild angina (CCSC I/
II) pre-EECP (odds ratio 2.70, 95% CI 1.64 – 4.46).
Discussion
In this large cohort of patients with refractory angina
undergoing EECP, SHS exposure was an independent pre-
dictor of failure to achieve a reduction in angina class after
treatment among non-smokers. Only 68% of those non-
smoking subjects with SHS had a reduction in angina
class, compared to 79% of the non-smokers without SHS
exposure. This low level of angina reduction is compara-
ble to that achieved among current cigarette smokers
(66%). Moreover, the SHS group had a higher rate of
adverse unstable angina cardiac events during the course
of EECP compared to non-smokers without SHS expo-
sure.
Prior clinical studies observed impaired endothelium-
dependent vasorelaxation, the earliest sign of endothelial
dysfunction, in smokers [25-27]. Passive smokers, defined
as those with SHS exposure, exhibited abnormal endothe-
lium-dependent vasodilatation to a similar extent as that
seen with current smokers [28]. Sumida et al found that
passive smoking changes acetylcholine-induced coronary
artery relaxation into vasoconstriction [29]. In another
study, coronary flow reserve, although higher in non-
smokers than in active smokers under control conditions,
was similar in the two groups after a 30-minute exposure
to SHS [30]. These findings indicate that the relatively low
doses of toxins inhaled by passive smoking are sufficient
to elicit a strong acute response. It is noteworthy that the
effects of SHS are acute and substantial, nearly as large
compared to chronic active smoking (averaging between
80% and 90%) [31].
Table 1: Baseline Demographics and Clinical Characteristics of Non-Smokers Undergoing Enhanced External Counterpulsation
Variables No SHS Exposure (n = 918) SHS Exposure (n = 108) p-value
Age (years ± SD) 68.1 ± 10.7 66.1 ± 11.7 0.033
Male (%) 73.6 65.7 0.081
Hypertension (%) 81.4 83.2 0.66
Hyperlipidemia (%) 93.3 87.6 0.035
Diabetes mellitus (%) 43.6 40.7 0.57
Carotid artery disease (%) 24.9 24.3 0.90
Stroke (%) 6.8 13.2 0.018
Prior smoking (%) 61.0 72.4 0.023
Values are expressed as mean ± SD or percentagePage 3 of 7
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changes of endothelial function have not yet been com-
pletely elucidated, but they may be related, at least in part,
to the inactivation of nitric oxide (NO) [17]. Animal stud-
ies have suggested that passive smoking reduces the activ-
ity of endothelial NO synthase [possibly due to the action
of carbon monoxide (CO)] [32] and the endothelial
arginine content [33]. In accordance with these results, it
was shown that L-arginine supplementation prevented
endothelial dysfunction induced by SHS in rabbits [32]
and reduced the infarct size in SHS-exposed rats [34].
EECP has been shown to increase c-GMP production,
which promotes vascular smooth muscle tone and
improves arterial function [35]. EECP also progressively
increased plasma nitric oxide levels in patients who
received 1-hour daily treatments over 6 weeks by 62%
compared to baseline improving endothelial function
[36]. Therefore, passive smoking could attenuate the vas-
cular effects of EECP by preventing the release of nitric
oxide induced by the shear forces generated by EECP.
A limitation of this analysis was the assessment of SHS
exposure. By defining SHS exposure as only house-hold
exposure, we may have underestimated the proportion of
subjects with occupational SHS. However, the vast major-
ity of patients undergoing EECP have severe angina, and
are not employed outside the home. Self-reporting of the
SHS status may be a limitation. There may be other
unmeasured confounding variables, such as obesity, poor
diet, and physical inactivity, which may be associated
with SHS. Our database was not able to capture these
potential confounding variables. The IEPR-2 Registry was
designed as a cohort study of patients undergoing EECP
and provides a rich data set for exploration. As with many
analyses of the Registry data, the SHS hypothesis was not
pre-specified; this should be kept in mind in the interpre-
tation of the findings.
Table 2: Baseline Coronary Disease Factors and Revascularization Status of Non-Smokers Undergoing Enhanced External 
Counterpulsation
Variables No SHS Exposure (n = 918) SHS Exposure (n = 108) p-value
Interval since CAD diagnosis (yrs) 11.5 ± 8.7 10.9 ± 8.2 0.69
Prior myocardial infarction (%) 69.9 74.8 0.30
Heart failure (%) 24.5 26.4 0.66
Ischemic cardiomyopathy (%) 35.2 41.1 0.23
Left ventricular ejection fraction (%) 47.3 ± 14.4 45.4 ± 14.7 0.25
Prior PCI or CABG (%) 90.4 85.2 0.091






Values are expressed as mean ± SD or percentage
Table 3: Clinical Outcomes after Enhanced External Counterpulsation of Non-Smokers Undergoing Enhanced External 
Counterpulsation
Variables No SHS Exposure (n = 918) SHS Exposure (n = 108) p-value
Death (%) 0.4 1.9 0.12
Myocardial infarction (%) 1.4 1.9 0.67
Unstable angina (%) 2.6 8.3 0.0014
Heart failure exacerbation (%) 1.4 2.8 0.28
Coronary bypass surgery (%) 0.3 0.0 0.55
Percutaneous coronary intervention (%) 1.1 1.9 0.37
MACE (Death/MI/CABG/PCI) (%) 2.8 5.6 0.12
Anginal status (%) 0.044
No angina 16.3 17.9
Class I 24.2 16.0
Class II 37.0 31.1
Class III 17.3 23.6
Class IV 5.3 11.3
Angina decreased ≥ 1 class 79.2 67.9 0.0082
Values are expressed as mean ± SD or percentagePage 4 of 7
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In conclusion, SHS may reduce the anti-anginal effects of
EECP among non-smokers. This reduced success rate of
EECP in SHS non-smokers is comparable to that seen in
current cigarette smokers. These findings are consistent
with studies showing that SHS exposure reduces nitric
oxide production, which is an important mechanism for
the clinical benefit seen with EECP.
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